Madrigal Pharmaceuticals

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$62,175
$14,638
$0
$770
Gross Profit
60,023
13,735
-168
628
EBITDA
-116,304
-162,270
-151,869
-117,034
EBIT
-162,537
-152,037
-117,176
Net Income
-106,964
-151,971
-147,541
-112,194
Net Change In Cash
62,175
14,638
0
770
Free Cash Flow
-62,763
-140,076
-149,514
-80,969
Cash
232,684
499,597
622,517
99,915
Basic Shares
21,745
21,402
20,001
19,760

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$0
$0
$37
$21
Gross Profit
-527
-467
273
21
EBITDA
-379,969
-291,386
-242,077
-206,202
EBIT
-380,496
-291,853
-242,482
-206,673
Net Income
-373,630
-299,314
-241,078
-197,444
Net Change In Cash
0
0
37
21
Cost of Revenue
295,280
-17,735
7,307
Free Cash Flow
-325,709
-225,074
-184,126
-157,895
Cash
99,915
331,549
36,269
54,004
Basic Shares
18,687
17,137
16,535
15,446

Earnings Calls

Quarter EPS
2024-09-30
-$4.92
2024-06-30
-$7.10
2024-03-31
-$7.38
2023-12-31
-$5.68